Profile change history

What changed for KPV?

A deterministic history of records added to PeptideScanner and preserved profile or record revisions connected through the reviewed KPV identity.

15Total events
13Record additions
2Version changes
7Cited source years

Before and after

Preserved version changes

Profile status changed

KPV profile

We added a plain-language reader guide with cited answers, re-checked FDA’s KPV briefing, and added HHS’s October 30, 2026 draft enforcement-discretion policy, which lists KPV acetate. FDA has not issued a final 503A rule.

PeptideScanner change date
November 14, 2026
Evidence lane
Profile

Status

Before
FDA compounding assessment in the cited records
After
Not an FDA-approved drug

Profile summary

Before
A tripeptide discussed in FDA briefing material for a 2026 pharmacy-compounding advisory-committee meeting.
After
A three-amino-acid peptide that is not FDA-approved. FDA’s 2026 review found no studies of KPV in people.

Evidence note

Before
FDA's July 2026 briefing evaluates KPV-related bulk drug substances for pharmacy compounding. The briefing is an advisory-process assessment, not a final regulatory determination.
After
FDA staff recommended in May 2026 against adding KPV to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists KPV acetate among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions; it does not make KPV an FDA-approved drug.

Cited source records

Before
fda-kpv-briefing, fda-pcac-peptide-meeting-2026
After
fda-kpv-briefing, fda-pcac-peptide-meeting-2026, fda-bulk-peptide-risks, federal-register-2026-07361-0aed508462b2, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026

Named organizations

Before
U.S. Food and Drug Administration [sources: fda-kpv-briefing, fda-pcac-peptide-meeting-2026]
After
U.S. Food and Drug Administration [sources: fda-kpv-briefing, fda-pcac-peptide-meeting-2026]; U.S. Department of Health and Human Services [sources: hhs-503a-peptide-enforcement-discretion-notice-2026]

Claim citations

Before
name: fda-kpv-briefing; aliases: fda-kpv-briefing; category: fda-kpv-briefing, fda-pcac-peptide-meeting-2026; status: fda-kpv-briefing; summary: fda-kpv-briefing, fda-pcac-peptide-meeting-2026; evidenceNote: fda-kpv-briefing
After
name: fda-kpv-briefing; aliases: fda-kpv-briefing; category: fda-kpv-briefing, fda-pcac-peptide-meeting-2026; status: fda-kpv-briefing; summary: fda-kpv-briefing; evidenceNote: fda-kpv-briefing, fda-pcac-peptide-meeting-2026, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026
Correction

KPV profile

We narrowed the status wording to what the dated FDA briefing establishes. A briefing prepared for an advisory process does not establish the current absence of a later final decision. Related substance identities remain distinct.

PeptideScanner change date
September 15, 2026
Evidence lane
Profile

Status

Before
FDA compounding safety review; final determination pending
After
FDA compounding assessment in the cited records

Evidence note

Before
FDA's KPV briefing describes evidence and safety questions presented to the advisory committee. Committee recommendations are nonbinding, and FDA says its final determination will follow completion of the committee process and relevant reviews.
After
FDA's July 2026 briefing evaluates KPV-related bulk drug substances for pharmacy compounding. The briefing is an advisory-process assessment, not a final regulatory determination.

Related names

Before
None recorded
After
Lys-Pro-Val

Claim citations

Before
name: fda-kpv-briefing; aliases: fda-kpv-briefing; category: fda-kpv-briefing, fda-pcac-peptide-meeting-2026; status: fda-kpv-briefing, fda-pcac-peptide-meeting-2026; summary: fda-kpv-briefing, fda-pcac-peptide-meeting-2026; evidenceNote: fda-kpv-briefing, fda-pcac-peptide-meeting-2026
After
name: fda-kpv-briefing; aliases: fda-kpv-briefing; category: fda-kpv-briefing, fda-pcac-peptide-meeting-2026; status: fda-kpv-briefing; summary: fda-kpv-briefing, fda-pcac-peptide-meeting-2026; evidenceNote: fda-kpv-briefing

Collection chronology

Evidence added to PeptideScanner

Browse all 13 connected records →

Showing the latest 13 additions by PeptideScanner publication date; the complete connected record set remains available on the cross-source timeline. Most recent addition: August 21, 2026.

Record added

Federal Register notice 2026-07361

The Federal Register published notice 2026-07361, attributed to FDA and its parent HHS department, on 2026-04-16. Its official title is “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List,” and PeptideScanner's exact reviewed identity mapping connects the document to BPC-157, Emideltide, Epitalon, KPV, MOTS-c, Semax and TB-500.

PeptideScanner change date
August 21, 2026
Cited source date
April 16, 2026
Evidence lane
Regulatory
Record added

PubMed record PMID 34547895

PeptideScanner retained PubMed bibliographic metadata for PMID 34547895 at 2026-07-30T19:58:34.757Z. PubMed recorded a metadata revision date of 2021-10-21 and an Entrez history date of 2021-09-22. PeptideScanner associated this retained record with the identity slug kpv. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 12, 2026
Cited source date
October 21, 2021
Evidence lane
Literature metadata
Record added

PubMed record PMID 34846053

PeptideScanner retained PubMed bibliographic metadata for PMID 34846053 at 2026-07-30T19:56:20.406Z. PubMed recorded a metadata revision date of 2021-12-23 and an Entrez history date of 2021-11-30. PeptideScanner associated this retained record with the identity slug kpv. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 12, 2026
Cited source date
December 23, 2021
Evidence lane
Literature metadata
Record added

PubMed record PMID 22837805

PeptideScanner retained PubMed bibliographic metadata for PMID 22837805 at 2026-07-30T19:58:22.828Z. PubMed recorded a metadata revision date of 2021-10-21 and an Entrez history date of 2012-07-28. PeptideScanner associated this retained record with the identity slug kpv. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 11, 2026
Cited source date
October 21, 2021
Evidence lane
Literature metadata
Record added

PubMed record PMID 25298219

PeptideScanner retained PubMed bibliographic metadata for PMID 25298219 at 2026-07-30T20:43:08.957Z. PubMed recorded a metadata revision date of 2019-12-10 and an Entrez history date of 2014-10-10. PeptideScanner associated this retained record with the identity slug kpv. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 11, 2026
Cited source date
December 10, 2019
Evidence lane
Literature metadata
Record added

PubMed record PMID 27458604

PeptideScanner retained PubMed bibliographic metadata for PMID 27458604 at 2026-07-30T18:28:30.778Z. PubMed recorded a metadata revision date of 2025-05-30 and an Entrez history date of 2016-07-27. PeptideScanner associated this retained record with the identity slug kpv. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 11, 2026
Cited source date
May 30, 2025
Evidence lane
Literature metadata
Record added

PubMed record PMID 29953505

PeptideScanner retained PubMed bibliographic metadata for PMID 29953505 at 2026-07-30T21:09:28.939Z. PubMed recorded a metadata revision date of 2018-12-19 and an Entrez history date of 2018-06-29. PeptideScanner associated this retained record with the identity slug kpv. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 11, 2026
Cited source date
December 19, 2018
Evidence lane
Literature metadata
Record added

PubMed record PMID 15102092

PeptideScanner retained PubMed bibliographic metadata for PMID 15102092 at 2026-07-30T21:56:55.933Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 2004-04-23. PeptideScanner associated this retained record with the identity slug kpv. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 10, 2026
Cited source date
November 21, 2013
Evidence lane
Literature metadata
Record added

PubMed record PMID 18092346

PeptideScanner retained PubMed bibliographic metadata for PMID 18092346 at 2026-07-30T21:10:56.892Z. PubMed recorded a metadata revision date of 2018-09-13 and an Entrez history date of 2007-12-20. PeptideScanner associated this retained record with the identity slug kpv. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 10, 2026
Cited source date
September 13, 2018
Evidence lane
Literature metadata
Record added

PubMed record PMID 28343991

PeptideScanner retained PubMed bibliographic metadata for PMID 28343991 at 2026-07-30T21:12:28.720Z. PubMed recorded a metadata revision date of 2018-04-05 and an Entrez history date of 2017-03-28. PeptideScanner associated this retained record with the identity slug kpv. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 10, 2026
Cited source date
April 5, 2018
Evidence lane
Literature metadata
Record added

PubMed record PMID 39252648

PeptideScanner retained PubMed bibliographic metadata for PMID 39252648 at 2026-07-30T16:25:12.445Z. PubMed recorded a metadata revision date of 2026-02-17 and an Entrez history date of 2024-09-10. PeptideScanner associated this retained record with the identity slug kpv. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 10, 2026
Cited source date
February 17, 2026
Evidence lane
Literature metadata
Record added

PubMed record PMID 6785126

PeptideScanner retained PubMed bibliographic metadata for PMID 6785126 at 2026-07-30T23:04:35.983Z. PubMed recorded a metadata revision date of 2003-11-14 and an Entrez history date of 1981-01-01. PeptideScanner associated this retained record with the identity slug kpv. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 10, 2026
Cited source date
November 14, 2003
Evidence lane
Literature metadata
Record added

FDA committee met on seven peptide-related groups of bulk drug substances

FDA convened its Pharmacy Compounding Advisory Committee on July 23-24, 2026, to discuss free-base and acetate bulk drug substances across seven peptide-related groups.

PeptideScanner change date
July 29, 2026
Cited source date
July 24, 2026
Evidence lane
Regulatory